Vault-13

Kynam Capital Management, LP

PRINCETON, NJ · CIK 1907884 · 13F filing filed 2022-08-15

SEC-registered investment adviser since 2022 · limited partnership

As an employer

$387.6m reported value +26.0% vs Q1 2022
31positions
79.4%in top 10
3 new 17 added 11 reduced 3 sold out vs Q1 2022

Options: 1 call positions ($2.5m notional), 2 put positions ($1.5m notional) – listed below, not included above.

Holdings, Q2 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 GLOBAL BLOOD THERAPEUTICS IN COM GBT GBT 2,200,000 $70.3m18.13% 18.13% AddedShares held: Q3 2021 —, Q4 2021 992.9k, Q1 2022 1.3m, Q2 2022 2.2m +860.7k +860,678 64.3%
2 SYNDAX PHARMACEUTICALS INC COM SNDX SNDX 2,512,240 $48.3m12.47% 12.47% AddedShares held: Q3 2021 —, Q4 2021 956.2k, Q1 2022 1.9m, Q2 2022 2.5m +579.4k +579,440 30.0%
3 NATERA INC COM NTRA NTRA 1,239,047 $43.9m11.33% 11.33% AddedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 966.4k, Q2 2022 1.2m +272.6k +272,647 28.2%
4 CELLDEX THERAPEUTICS INC NEW COM NEW CLDX CLDX 1,132,259 $30.5m7.88% 7.88% AddedShares held: Q3 2021 —, Q4 2021 226.7k, Q1 2022 753.0k, Q2 2022 1.1m +379.2k +379,225 50.4%
5 TRAVERE THERAPEUTICS INC COM TVTX TVTX 1,235,151 $29.9m7.72% 7.72% AddedShares held: Q3 2021 —, Q4 2021 182.1k, Q1 2022 870.9k, Q2 2022 1.2m +364.2k +364,233 41.8%
6 VERA THERAPEUTICS INC CL A VERA VERA 1,522,712 $20.7m5.35% 5.35% AddedShares held: Q3 2021 —, Q4 2021 253.4k, Q1 2022 502.3k, Q2 2022 1.5m +1.0m +1,020,384 203.1%
7 GOSSAMER BIO INC COM GOSS GOSS 2,350,448 $19.7m5.08% 5.08% AddedShares held: Q3 2021 —, Q4 2021 1.0m, Q1 2022 1.8m, Q2 2022 2.4m +517.7k +517,744 28.2%
8 BIOGEN INC COM BIIB BIIB 78,951 $16.1m4.15% 4.15% AddedShares held: Q3 2021 —, Q4 2021 40.0k, Q1 2022 38.2k, Q2 2022 79.0k +40.7k +40,715 106.5%
9 VAXCYTE INC COM PCVX PCVX 723,781 $15.7m4.06% 4.06% AddedShares held: Q3 2021 —, Q4 2021 211.5k, Q1 2022 579.6k, Q2 2022 723.8k +144.1k +144,141 24.9%
10 BURNING ROCK BIOTECH LTD SPONSORED ADS SPONSORED ADS 4,300,000 $12.5m3.23% 3.23% AddedShares held: Q3 2021 —, Q4 2021 382.5k, Q1 2022 773.1k, Q2 2022 4.3m +3.5m +3,526,886 456.2%
11 BIOCRYST PHARMACEUTICALS INC COM BCRX BCRX 936,563 $9.9m2.56% 2.56% NewShares held: Q3 2021 —, Q4 2021 0, Q1 2022 0, Q2 2022 936.6k
12 AMICUS THERAPEUTICS INC COM FOLD FOLD 900,000 $9.7m2.49% 2.49% AddedShares held: Q3 2021 —, Q4 2021 573.7k, Q1 2022 573.5k, Q2 2022 900.0k +326.5k +326,484 56.9%
13 COGENT BIOSCIENCES INC COM COGT COGT 1,000,000 $9.0m2.33% 2.33% NewShares held: Q3 2021 —, Q4 2021 150.0k, Q1 2022 0, Q2 2022 1.0m
14 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 590,143 $6.8m1.76% 1.76% AddedShares held: Q3 2021 —, Q4 2021 287.9k, Q1 2022 589.8k, Q2 2022 590.1k +317 +317 0.1%
15 LIQUIDIA CORPORATION COM NEW LQDA LQDA 1,500,718 $6.5m1.69% 1.69% AddedShares held: Q3 2021 —, Q4 2021 1.4m, Q1 2022 1.2m, Q2 2022 1.5m +341.0k +341,044 29.4%
16 AMARIN CORP PLC SPONS ADR NEW SPONS ADR NEW 4,009,893 $6.0m1.54% 1.54% AddedShares held: Q3 2021 —, Q4 2021 2.2m, Q1 2022 2.3m, Q2 2022 4.0m +1.7m +1,715,811 74.8%
17 WAVE LIFE SCIENCES LTD SHS 96663EUR 96663EUR 1,696,735 $5.5m1.42% 1.42% ReducedShares held: Q3 2021 —, Q4 2021 1.5m, Q1 2022 1.9m, Q2 2022 1.7m -215.0k -214,993 -11.2%
18 XENON PHARMACEUTICALS INC COM XENE XENE 175,000 $5.3m1.37% 1.37% ReducedShares held: Q3 2021 —, Q4 2021 670.1k, Q1 2022 483.3k, Q2 2022 175.0k -308.3k -308,270 -63.8%
19 CONCERT PHARMACEUTICALS INC COM CNCE CNCE 1,000,000 $4.2m1.09% 1.09% NewShares held: Q3 2021 —, Q4 2021 0, Q1 2022 0, Q2 2022 1.0m
20 CENTESSA PHARMACEUTICALS PLC SPONSORED ADS SPONSORED ADS 757,848 $3.7m0.95% 0.95% AddedShares held: Q3 2021 —, Q4 2021 239.0k, Q1 2022 669.1k, Q2 2022 757.8k +88.7k +88,748 13.3%
21 MERUS N V COM MRUS MRUS 103,627 $2.3m0.61% 0.61% ReducedShares held: Q3 2021 —, Q4 2021 122.2k, Q1 2022 116.8k, Q2 2022 103.6k -13.1k -13,137 -11.2%
22 FATE THERAPEUTICS INC COM FATE FATE 81,064 $2.0m0.52% 0.52% ReducedShares held: Q3 2021 —, Q4 2021 95.6k, Q1 2022 91.3k, Q2 2022 81.1k -10.3k -10,273 -11.2%
23 AFFIMED N V COM COM 701,029 $1.9m0.50% 0.50% AddedShares held: Q3 2021 —, Q4 2021 364.0k, Q1 2022 348.0k, Q2 2022 701.0k +353.1k +353,064 101.5%
24 AKOUOS INC COM COM 383,784 $1.8m0.46% 0.46% ReducedShares held: Q3 2021 —, Q4 2021 99.0k, Q1 2022 387.9k, Q2 2022 383.8k -4.1k -4,108 -1.1%
25 PUMA BIOTECHNOLOGY INC COM PBYI PBYI 579,915 $1.7m0.43% 0.43% ReducedShares held: Q3 2021 —, Q4 2021 683.6k, Q1 2022 653.4k, Q2 2022 579.9k -73.5k -73,530 -11.2%
26 OLEMA PHARMACEUTICALS INC COM OLMA OLMA 249,229 $1.0m0.26% 0.26% ReducedShares held: Q3 2021 —, Q4 2021 293.8k, Q1 2022 280.8k, Q2 2022 249.2k -31.6k -31,598 -11.2%
27 SERES THERAPEUTICS INC COM COM 258,647 $887.0k0.23% 0.23% ReducedShares held: Q3 2021 —, Q4 2021 304.9k, Q1 2022 291.4k, Q2 2022 258.6k -32.8k -32,796 -11.2%
28 CONNECT BIOPHARMA HLDGS LTD ADS ADS 739,649 $643.0k0.17% 0.17% AddedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 227.8k, Q2 2022 739.6k +511.9k +511,890 224.8%
29 CABALETTA BIO INC COM CABA CABA 546,800 $580.0k0.15% 0.15% ReducedShares held: Q3 2021 —, Q4 2021 644.6k, Q1 2022 616.1k, Q2 2022 546.8k -69.3k -69,325 -11.2%
30 CATALYST BIOSCIENCES INC COM NEW COM NEW 93,434 $166.0k0.04% 0.04% ReducedShares held: Q3 2021 —, Q4 2021 111.0k, Q1 2022 106.1k, Q2 2022 93.4k -12.7k -12,655 -11.9%
31 NEOLEUKIN THERAPEUTICS INC COM COM 124,701 $128.0k0.03% 0.03% ReducedShares held: Q3 2021 —, Q4 2021 147.0k, Q1 2022 140.5k, Q2 2022 124.7k -15.8k -15,807 -11.2%

Sold out since Q1 2022

SecurityTickerShares held beforeValue then
SIERRA ONCOLOGY INC 193,280 $6.2m193.3k shares
RADIUS HEALTH INC RDUS RDUS 185,514 $1.6m185.5k shares
KRYSTAL BIOTECH INC KRYS KRYS 18,393 $1.2m18.4k shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
CELLDEX THERAPEUTICS INC NEW CLDX · Call CLDXCall 246,400 $2.5m246.4k shares New
ALNYLAM PHARMACEUTICALS INC ALNY · Put ALNYPut 50,000 $925.0k50.0k shares New
KARUNA THERAPEUTICS INC Put Put 38,900 $578.0k38.9k shares New

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
BURNING ROCK BIOTECH LTD 13G · filed 2026-05-15 14.0% +3.0 pts 13G 2026-05-15
SYNDAX PHARMACEUTICALS INC SNDX · 13G · filed 2025-02-14 SNDX 10.0%≈ $186.2m 13G 2025-02-14
CYTOMX THERAPEUTICS INC CTMX · 13G · filed 2026-08-14 CTMX 10.0% +3.1 pts 13G 2026-08-14
CELLDEX THERAPEUTICS INC NEW CLDX · 13G · filed 2026-08-14 CLDX 6.8% -2.0 pts 13G 2026-08-14
VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 VRDN 5.7% +4.2 pts 13G 2026-08-14
SUTRO BIOPHARMA INC 13G · filed 2026-05-15 5.3% -1.2 pts 13G 2026-05-15
CULLINAN THERAPEUTICS INC CGEM · 13G · filed 2026-03-04 CGEM 5.3%≈ $56.7m new 13G 2026-03-04